Hims & Hers Health Inc. Aktie News

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company,” NYSE: HIMS), the leading health and wellness platform, today announced that its Board of Directors has authorized a share repurchase program of up to $250 million of outstanding Class A common stock over the next three years. This new program follows the successful completion of the Company's prior $100 mi...

Hims & Hers Health has appointed Deb Autor as its first chief policy officer to lead public policy and government functions, the telehealth firm said on Monday.

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the appointment of Deb Autor as the company's first Chief Policy Officer. In this new role, Autor will collaborate with other stakeholders, including consumers, telehealth platforms, providers, advocacy groups, medical associations, pharmaceutical companies, medtech i...

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the launch of Labs, a new way for customers to understand their overall health and identify ways to improve and maintain it. Labs measures key markers over time and provides doctor-developed action plans that can power real shifts in health outcomes. With this new, pr...

The telehealth platform expects the new offering to add to its user base as it draws customers looking to prevent future health issues.

The health industry offers opportunities beyond the big, well-known names. TransMedics Group boasts a sticky business model that is highly profitable.

These stocks have a lot more to offer than GLP-1 success. Eli Lilly is one of the oldest pharmaceutical companies in the world, is insanely profitable, and boasts a wide range of portfolio stars.

We're turning bullish on Hims & Hers now that we believe the worst is priced in. Q3 results confirm that the growth story remains centered around personalized plans driving 50% Y/Y revenue growth. Hence, it see longer-term financial leverage from scaling that business model. The "active discussions" with Novo Nordisk are a cherry on top but we see green shoots outside of weight-loss drugs that'...